Prospective study reveals that a neutrophilic phenotype increases adverse in-hospital outcomes in asthma-bronchiectasis overlap syndrome, indicating potential for acute risk stratification.
Background Exacerbations of asthma-bronchiectasis overlap syndrome (ABOS) are clinically heterogeneous, with poorly defined inflammatory phenotypes and their links to outcomes.Objective To identify phenotypes in ABOS exacerbations and their associations with in-hospital outcomes.Methods In this prospective study, 343 patients with ABOS exacerbation were clustered using multidimensional data; findings were validated in 147 independent patients. Associations between phenotypes and outcomes (Intensive Care Unit [ICU] admission, invasive mechanical ventilation [IMV], mortality) were analyzed via multivariable regression.Results Three phenotypes were identified: female-paucigranulocytic (Cluster T1), young male-eosinophilic (Cluster T2), and neutrophilic-lymphopenic (Cluster T3). Cluster T3 had the highest risks of ICU admission (adjusted relative risk [RRadj] = 7.84, 95% CI: 2.21–27.78), IMV (RRadj=7.84, 95% CI: 2.21–27.78), and mortality (RRadj=6.86, 95% CI: 2.33–37.67). Neutrophilia showed a dose-dependent association with adverse outcomes (Ptrend<0.001), with elevated levels independently predicting composite outcomes (RRadj=2.06, 95% CI: 1.42–3.03).Conclusions ABOS exacerbations exhibit distinct inflammatory phenotypes. The neutrophilic-lymphopenic phenotype strongly predicts in-hospital adverse outcomes, highlighting its potential for acute risk stratification in hospitalized patients.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: